Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This is a safety and dose finding efficacy study to evaluate the effects of BGP-15 over the
dose range of 100 mg/day to 400 mg/day. Doses are applied once or twice a day for 13 weeks as
add-on therapy to the combination of metformin and sulfonylurea treatment or metformin alone
in patients with Type 2 Diabetes Mellitus.
Phase:
Phase 2
Details
Lead Sponsor:
N-Gene Research Laboratories, Inc.
Collaborators:
Barc NV Haupt Pharma Wülfing GmbH Integrium Kinexum LLC Msource Medical Development GmbH Thermo Fisher Scientific